Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12620000647932
Ethics application status
Approved
Date submitted
12/05/2020
Date registered
4/06/2020
Date last updated
29/06/2022
Date data sharing statement initially provided
4/06/2020
Type of registration
Prospectively registered

Titles & IDs
Public title
Training Inhibitory Control in Adolescents in Attention-Deficit/Hyperactivity Disorder
Scientific title
Training Inhibitory Control in Adolescents in Attention-Deficit/Hyperactivity Disorder: A randomised controlled trial of the Alfi Virtual Reality programme
Secondary ID [1] 300865 0
None
Universal Trial Number (UTN)
U1111-1250-4678
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Attention-Deficit/Hyperactivity Disorder 317243 0
Condition category
Condition code
Mental Health 315377 315377 0 0
Other mental health disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
The Alfi Virtual Reality programme (Alfi VR) is a novel, adaptive, game-based program designed to train inhibitory control in adolescents. Alfi VR is delivered using a HTC Vive headset and controllers, using immersive virtual reality technology. Participants complete 16 twice weekly training sessions over a period of 8 weeks. Training is delivered individually, face to face by trained research assistants. In the game participants are required to complete an Anticipated Response Task, set in a fantasy world where they must protect a magic crystal from dragons. Each training sessions last approximately 20 minutes. Participants must initiate a response and then either complete or inhibit the response based on visual cues. Training sessions are completed at the participants school, during class time. Compliance is defined as having completed 12 of the 16 allocated training sessions.
Intervention code [1] 317441 0
Treatment: Devices
Intervention code [2] 317651 0
Treatment: Other
Comparator / control treatment
This trial will use a treatment-as-usual control group. The treatment as usual is defined as participants attending their usual classes and programs within the school setting.
Control group
Active

Outcomes
Primary outcome [1] 323626 0
Response inhibition as measured by the Stop-signal reaction time from the Anticipated Response Task
Timepoint [1] 323626 0
Post-training assessment. This assessment will occur one week after the completion of the intervention; with the assessment to be scheduled no less than 3 days and no more than 10 days after the final training session.
Secondary outcome [1] 382422 0
Risk taking as measured by the Balloon Analogue Risk Task for Youth
Timepoint [1] 382422 0
Post-training assessment. This assessment will occur one week after the completion of the intervention; with the assessment to be scheduled no less than 3 days and no more than 10 days after the final training session.
Secondary outcome [2] 382423 0
Impulsivity as measured by the UPPS-P
Timepoint [2] 382423 0
Post-training assessment. This assessment will occur one week after the completion of the intervention; with the assessment to be scheduled no less than 3 days and no more than 10 days after the final training session.
Secondary outcome [3] 382424 0
Behavioural attention as measured by the SWAN
Timepoint [3] 382424 0
Post-training assessment. This assessment will occur one week after the completion of the intervention; with the assessment to be scheduled no less than 3 days and no more than 10 days after the final training session.
Secondary outcome [4] 382425 0
Executive function as measured by the BRIEF
Timepoint [4] 382425 0
Post-training assessment. This assessment will occur one week after the completion of the intervention; with the assessment to be scheduled no less than 3 days and no more than 10 days after the final training session.
Secondary outcome [5] 382426 0
Social functioning as measured by the Social Skills Questionnaire
Timepoint [5] 382426 0
Post-training assessment. This assessment will occur one week after the completion of the intervention; with the assessment to be scheduled no less than 3 days and no more than 10 days after the final training session.
Secondary outcome [6] 382427 0
Working memory as measured by the Digit Span
Timepoint [6] 382427 0
Post-training assessment. This assessment will occur one week after the completion of the intervention; with the assessment to be scheduled no less than 3 days and no more than 10 days after the final training session.
Secondary outcome [7] 383234 0
Emotion regulation as measured by the Perth Emotion Regulation Competency Inventory (PERCI)
Timepoint [7] 383234 0
Post-training assessment. This assessment will occur one week after the completion of the intervention; with the assessment to be scheduled no less than 3 days and no more than 10 days after the final training session.
Secondary outcome [8] 411347 0
Attention (sustained, selective and executive control) as measured by the Attention Network task (ANT)
Timepoint [8] 411347 0
Post-training assessment. This assessment will occur one week after the completion of the intervention; with the assessment to be scheduled no less than 3 days and no more than 10 days after the final training session.

Eligibility
Key inclusion criteria
Key inclusion criteria include;
- aged 13 years to 17 years 11 months
- has a diagnosis of ADHD, or an attention deficit (defined as a T-score above 60 on the Inattention, Hyperactive, DSM-Inattention or DSM-Hyperactive subscales of the Conners-3 Parent Rating Scale)
Minimum age
13 Years
Maximum age
17 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Key exclusion criteria include;
- History of epilepsy or seizures, loss of awareness, or other symptoms linked to an epileptic condition.
- Previous diagnosis of an intellectual or borderline delay, or who score an IQ <80 as measured by the KBIT-2.
- Previous brain injury or neurological disease.
- Sensory (e.g. colour blindness) or physical impairment that affects capacity to comprehend and follow study instruction.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Group allocation will be completed by a research assistant from within the research group, who is not otherwise assigned to the trial and therefore is not involved in recruitment, screening, enrollment or assessment. Allocation sequences will be generated and concealed in sequential, opaque, sealed envelopes. The participant's study ID will be provided to the research assistant to be recorded on the envelope, prior to the envelope being provided to trial researchers responsible for enrollment and assessment.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Stratified, block randomisation using a computer program (R)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Possible mediating and predictive factors such as anxiety, emotional and behavioural problems, Autism features, family functioning and socioeconomic status will be assessed.

Anxiety, emotional and behavioural problems and family functioning will be assessed at the baseline assessment and the post-training assessment using the Spence Children's Anxiety Scale, The Child Behaviour Checklist (Parent report) and the Family Assessment Device respectively.

Socio-economic status and Autism features will be measured during the screening and enrollment stage through use of a demographic questionnaire and the Social Responsiveness Scale 2nd Edition respectively.

Children will be screened using standardised measures of cognitive functioning (the Kaufman Brief Intelligence Test - 2nd Edition) and attention (the Conners-3 Parent Rating Scale) to confirm eligibility.

The NEPSY-II will be used to measure social cognition by assessing affect recognition and theory of mind.
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
A priori power analysis was conducted in G*Power V.3.1 to determine the necessary sample size required to detect significant changes in inhibitory control from pre-training (baseline) to post-training. A sample size of 98 was required for a Medium effect (f=0.25) and a power of 80%. The study will therefore aim to recruit 100 participants, with 50 per group assuming a 1:1 allocation ratio.

Latent Growth Curve Modelling will be used to compare primary and secondary outcomes from the post-training assessment across groups.

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
Actual
11/06/2020
Date of last participant enrolment
Anticipated
1/11/2021
Actual
4/01/2022
Date of last data collection
Anticipated
20/12/2021
Actual
7/04/2022
Sample size
Target
100
Accrual to date
Final
35
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment postcode(s) [1] 30141 0
3800 - Monash University

Funding & Sponsors
Funding source category [1] 305318 0
Charities/Societies/Foundations
Name [1] 305318 0
5point Foundation
Country [1] 305318 0
Australia
Primary sponsor type
Individual
Name
Kim Cornish
Address
Monash University
Wellington Road,
Clayton, VIC 3800
Country
Australia
Secondary sponsor category [1] 305988 0
None
Name [1] 305988 0
Address [1] 305988 0
Country [1] 305988 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 305657 0
Monash University HREC
Ethics committee address [1] 305657 0
Ethics committee country [1] 305657 0
Australia
Date submitted for ethics approval [1] 305657 0
06/09/2019
Approval date [1] 305657 0
21/10/2019
Ethics approval number [1] 305657 0
21530
Ethics committee name [2] 305877 0
Department of Education and Training
Ethics committee address [2] 305877 0
Ethics committee country [2] 305877 0
Australia
Date submitted for ethics approval [2] 305877 0
16/01/2020
Approval date [2] 305877 0
10/03/2020
Ethics approval number [2] 305877 0
2020_004271

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 101114 0
Dr Hannah Kirk
Address 101114 0
Monash University Wellington Road Clayton, VIC 3800
Country 101114 0
Australia
Phone 101114 0
+61 03 9905 0230
Fax 101114 0
Email 101114 0
[email protected]
Contact person for public queries
Name 101115 0
Hannah Kirk
Address 101115 0
Monash University Wellington Road Clayton, VIC 3800
Country 101115 0
Australia
Phone 101115 0
+61 03 9905 3255
Fax 101115 0
Email 101115 0
[email protected]
Contact person for scientific queries
Name 101116 0
Hannah Kirk
Address 101116 0
Monash University Wellington Road Clayton, VIC 3800
Country 101116 0
Australia
Phone 101116 0
+61 03 9905 3255
Fax 101116 0
Email 101116 0
[email protected]

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Data will be made available on case-by-case basis at the discretion of Primary Sponsor

Conditions for requesting access:
• -

What individual participant data might be shared?
• Relevant anonymised participant level data available on reasonable request to the researchers.

What types of analyses could be done with individual participant data?
• Undetermined; to be assessed on a case-by-case basis at the discretion of the Primary Sponsor

When can requests for individual participant data be made (start and end dates)?
From:
Data will be available following publication, with no determined end date

To:
-

Where can requests to access individual participant data be made, or data be obtained directly?
• Access subject to approvals by Principal Investigators Dr Hannah Kirk and Professor Kim Cornish
[email protected]
[email protected]

Are there extra considerations when requesting access to individual participant data?
No


What supporting documents are/will be available?

TypeCitationLinkEmailOther DetailsAttachment
Study protocol    A study protocol is being submitted for publicatio... [More Details]
Informed consent form    Study-related document.pdf
Ethical approval    Study-related document.pdf
Ethical approval    Study-related document.pdf


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
EmbaseTraining inhibitory control in adolescents with elevated attention deficit hyperactivity disorder traits: a randomised controlled trial of the Alfi Virtual Reality programme.2022https://dx.doi.org/10.1136/bmjopen-2022-061626
N.B. These documents automatically identified may not have been verified by the study sponsor.